M

Madrigal Pharmaceuticals
D

MDGL

347.35
USD
18.13
(5.51%)
Market Closed
Volume
24,213
EPS
-25
Div Yield
-
P/E
-14
Market Cap
7,575,844,871
OverviewSignalsIdeasNews
Related Instruments
    A
    AGIO
    -1.645
    (-2.97%)
    53.810 USD
    ALNY
    ALNY
    -22.650
    (-8.77%)
    235.480 USD
    A
    ARWR
    -2.890
    (-13.49%)
    18.540 USD
    C
    CRBP
    -0.950
    (-5.41%)
    16.610 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    V
    VKTX
    -3.960
    (-7.39%)
    49.620 USD
    More
News

Title: Madrigal Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.